Search

Your search keyword '"Open-angle glaucoma -- Drug therapy"' showing total 3 results
Start Over Descriptor "Open-angle glaucoma -- Drug therapy" Journal business wire
3 results on '"Open-angle glaucoma -- Drug therapy"'

1. Open-Angle Glaucoma (Ophthalmology) Drugs Development Research Report 2021: Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type - ResearchAndMarkets.com

Subjects
Ophthalmology -- Reports, Open-angle glaucoma -- Drug therapy, Industrial research -- Reports, Research and development, Business, Business, international
Abstract

DUBLIN -- The 'Open-Angle Glaucoma (Ophthalmology) - Drugs in Development, 2021' report has been added to ResearchAndMarkets.com's offering. Open-Angle Glaucoma (Ophthalmology) - Drugs in Development, 2021 provides an overview of [...]

Published
2021

2. Aerie Pharmaceuticals Announces U.S. FDA Approval of Rocklatan[TM] (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the Reduction of Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension

Subjects
United States. Food and Drug Administration, Prostaglandins, Ophthalmic drugs, Drug approval, Open-angle glaucoma -- Drug therapy, Hypertension -- Drug therapy, Business, Business, international, Rhopressa (Medication), Rocklatan (Medication)
Abstract

- First and Only Once-Daily, Fixed-Dose Combination of a Prostaglandin Analog and a Rho Kinase (ROCK) Inhibitor - - Rocklatan[TM] Demonstrated Statistical Superiority over Widely-Prescribed First-Line Agent Latanoprost - DURHAM, [...]

Published
2019

3. Aerie Pharmaceuticals Announces U.S. FDA Approval of Rhopressa[R] (netarsudil ophthalmic solution) 0.02% for the Lowering of Elevated Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension

Subjects
United States. Food and Drug Administration, Ophthalmic agents, Hypertension -- Drug therapy, Drug approval, Open-angle glaucoma -- Drug therapy, Business, Business, international
Abstract

Product Approved Ahead of the Scheduled PDUFA Date of February 28, 2018 IRVINE, Calif. -- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), an ophthalmic pharmaceutical company focused on the [...]

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results